Clinical evidence for the role of trichomonas vaginalis in regulation of secretory leukocyte protease inhibitor in the female genital tract

Journal of Infectious Diseases

Volumn 207, Issue 9, 2013, Pages 1462-1470

  Huppert, Jill S ^a   Huang, Bin ^a   Chen, Chen ^a   Dawood, Hassan Y ^b   Fichorova, Raina N ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adolescent; Bacterial; human; Sexually Transmitted Diseases; SLPI protein; Trichomonas vaginalis; Vaginosis

Indexed keywords

SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; FEMALE; FEMALE GENITAL SYSTEM; HORMONAL CONTRACEPTION; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INNATE IMMUNITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MYCOPLASMA GENITALIUM; NEISSERIA GONORRHOEAE; PARASITE IDENTIFICATION; PARASITE LOAD; PH; PRIORITY JOURNAL; RECURRENT INFECTION; RISK FACTOR; TRICHOMONAS VAGINALIS; TRICHOMONIASIS;

ADOLESCENT; BIOLOGICAL MARKERS; FEMALE; HUMANS; PARASITE LOAD; REPRODUCTIVE TRACT INFECTIONS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; TRICHOMONAS VAGINALIS; VAGINA; YOUNG ADULT;

EID: 84876001988     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit039     Document Type: Article

References (50)

1. Guerrieri D, Tateosian NL, Maffia PC, et al. Serine leucocyte proteinase inhibitor-treated monocyte inhibits human CD4(+) lymphocyte proliferation. Immunology 2011; 133:434-41.
2. Taborda NA, Catano JC, Delgado JC, Rugeles MT, Montoya CJ. Higher SLPI expression, lower immune activation, and increased frequency of immune cells in a cohort of Colombian HIV-1 controllers. J Acquir Immune Defic Syndr 2012; 60:12-9.
3. Ghosh M, Fahey JV, Shen Z, et al. Anti-HIV activity in cervicalvaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 2010; 5:e11366.
4. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:418-28. (Pubitemid 32718505)
5. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183:653-6. (Pubitemid 32147523)
6. Mitchell CM, Balkus J, Agnew KJ, et al. Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses 2008; 24:667-71. (Pubitemid 351748782)
7. Novak RM, Donoval BA, Graham PJ, et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007; 14:1102-7. (Pubitemid 47518076)
8. Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis 2010; 202:1907-15.
9. Fichorova RN. Impact of T. vaginalis infection on innate immune responses and reproductive outcome. J Reprod Immunol 2009; 83: 185-9.
10. King AE, Kelly RW, Sallenave JM, Bocking AD, Challis JR. Innate immune defences in the human uterus during pregnancy. Placenta 2007; 28:1099-106. (Pubitemid 47591363)
11. Kigozi GG, Brahmbhatt H, Wabwire-Mangen F, et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2003; 189:1398-400. (Pubitemid 37542180)
12. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487-93. (Pubitemid 32758500)
13. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998; 11: 300-17. (Pubitemid 28197355)
14. Fichorova RN, Trifonova RT, Gilbert RO, et al. Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect Immun 2006; 74:5773-9. (Pubitemid 44484563)
15. Yen S, Shafer MA, Moncada J, Campbell CJ, Flinn SD, Boyer CB. Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. Obstet Gynecol 2003; 102:927-33. (Pubitemid 37412279)
16. Simhan HN, Caritis SN, Krohn MA, Hillier SL. Elevated vaginal pH and neutrophils are associated strongly with early spontaneous preterm birth. Am J Obstet Gynecol 2003; 189:1150-4. (Pubitemid 37373912)
17. Yudin MH, Hillier SL, Wiesenfeld HC, Krohn MA, Amortegui AA, Sweet RL. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol 2003; 188:318-23. (Pubitemid 36249964)
18. Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, Heine RP. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000; 183:1243-8.
19. Draper D, Donohoe W, Mortimer L, Heine RP. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis 1998; 178:815-9. (Pubitemid 28397230)
20. Barousse MM, Theall KP, Van Der Pol B, Fortenberry JD, Orr DP, Fidel PL Jr. Susceptibility of middle adolescent females to sexually transmitted infections: impact of hormone contraception and sexual behaviors on vaginal immunity. Am J Reprod Immunol 2007; 58:159-68. (Pubitemid 47097382)
21. Scott ME, Ma Y, Farhat S, Shiboski S, Moscicki AB. Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol 2006; 26:222-32. (Pubitemid 43901651)
22. Huppert JS, Hesse EA, Bernard MC, Bates JR, Gaydos CA, Kahn JA. Accuracy and trust of self-testing for bacterial vaginosis. J Adolesc Health 2012; 51:400-5.
23. Schwebke JR, Hillier SL, Sobel JD, McGregor JA, Sweet RL. Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996; 88:573-6. (Pubitemid 26326021)
24. Gutman RE, Peipert JF, Weitzen S, Blume J. Evaluation of clinical methods for diagnosing bacterial vaginosis. Obstet Gynecol 2005; 105:551-6. (Pubitemid 40271221)
25. Huppert JS, Hesse E, Kim G, et al. Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians. Sex Transm Infect 2010; 86:514-9.
26. Geisler WM, Yu S, Venglarik M, Schwebke JR. Vaginal leucocyte counts in women with bacterial vaginosis: relation to vaginal and cervical infections. Sex Transm Infect 2004; 80:401-5. (Pubitemid 39389561)
27. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22. (Pubitemid 13221599)
28. Eschenbach DA, Hillier S, Critchlow C, Stevens C, DeRouen T, Holmes KK. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158:819-28.
29. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007; 45:194-8. (Pubitemid 47041010)
30. Mauck CK, Ballagh SA, Creinin MD, et al. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr 2008; 49:243-50.
31. Fichorova RN, Lee Y, Yamamoto HS, et al. Endobiont viruses sensed by the human host-beyond conventional antiparasitic therapy. PLOS One 2012; 7:e48418.
32. Borchardt KA, Zhang MZ, Shing H, Flink K. A comparison of the sensitivity of the InPouch TV, Diamond's and Trichosel media for detection of Trichomonas vaginalis. Genitourin Med 1997; 73:297-8. (Pubitemid 27376696)
33. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011; 49:4106-11.
34. Barenfanger J, Drake C, Hanson C. Timing of inoculation of the pouch makes no difference in increased detection of Trichomonas vaginalis by the InPouch TV method. J Clin Microbiol 2002; 40:1387-9. 79. (Pubitemid 34279905)
35. Wiese W, Patel SR, Patel SC, Ohl CA, Estrada CA. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med 2000; 108:301-8. (Pubitemid 30110459)
36. Ohlemeyer CL, Hornberger LL, Lynch DA, Swierkosz EM. Diagnosis of Trichomonas vaginalis in adolescent females: InPouch TV culture versus wet-mount microscopy. J Adolesc Health 1998; 22:205-8. (Pubitemid 28110168)
37. Wendel KA, Erbelding EJ, Gaydos CA, Rompalo AM. Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis 2002; 35:576-80.
38. Huppert JS, Batteiger BE, Braslins P, et al. Use of an immunochromatographic assay for rapid detection of Trichomonas vaginalis in vaginal specimens. J Clin Microbiol 2005; 43:684-7. (Pubitemid 40256019)
39. Andrea SB, Chapin KC. Comparison of Aptima Trichomonas vaginalis Transcription-Mediated Amplification Assay and BD Affirm VPIII for Detection of T. vaginalis in Symptomatic Women: Performance Parameters and Epidemiological Implications. J Clin Microbiol 2011; 49: 866-9.
40. Chapin K, Andrea S. APTIMA(R) Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens. Expert Rev Mol Diagn 2011; 11:679-88.
41. Garber GE. The laboratory diagnosis of Trichomonas vaginalis. Can J Infect Dis Med Microbiol 2005; 16:35-8. (Pubitemid 40470553)
42. Caliendo AM, Jordan JA, Green AM, Ingersoll J, Diclemente RJ, Wingood GM. Real-time PCR improves detection of Trichomonas vaginalis infection compared with culture using self-collected vaginal swabs. Infect Dis Obstet Gynecol 2005; 13:145-50. (Pubitemid 41445025)
43. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-63. (Pubitemid 27446562)
44. Benjamini Y, Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat 2000; 25:60-83.
45. Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM Jr. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis 2009; 48:259-60.
46. Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005; 192:2039-44. (Pubitemid 41779199)
47. Gatski M, Kissinger P. Observation of probable persistent, undetected Trichomonas vaginalis infection among HIV-positive women. Clin Infect Dis 2010; 51:114-5.
48. Roy S, Caillouette JC, Faden JS, Roy T, Ramos DE. Improving appropriate use of antifungal medications: the role of an over-thecounter vaginal pH self-test device. Infect Dis Obstet Gynecol 2003; 11:209-16. (Pubitemid 38101441)
49. Su HI, Schreiber CA, Fay C, et al. Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides. Contraception 2011; 84:525-32.
50. Fichorova RN, Yamamoto HS, Delaney ML, Onderdonk AB, Doncel GF. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. mBio 2011; 2:e00168-11.